Guangdong Hongye Pharmaceutical Technology

Guangdong Hongye Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Zhongshan, China, specializing in the discovery and development of innovative small molecule therapeutics for hematological malignancies and autoimmune disorders. The company's lead program, HZ-L105, is a highly selective BCL-2 inhibitor currently in Phase 1 clinical trials for mature B-cell malignancies, designed to overcome resistance mutations seen with first-generation inhibitors. Leveraging its proprietary BpProM technology platform for protein activity and homeostasis regulation, the company is also advancing a pipeline of JAK inhibitors, STAT3 inhibitors, and PROTAC-based degraders. Guangdong Hongye operates in strategic partnership with Hangzhou HealZen Therapeutics to accelerate the clinical translation of its oncology and immunology portfolio.